Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.00% $3.05
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 215.67 mill |
EPS: | -0.740 |
P/E: | -4.12 |
Earnings Date: | May 03, 2024 |
SharesOutstanding: | 70.71 mill |
Avg Daily Volume: | 0.211 mill |
RATING 2024-03-28 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | |||||
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.12 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.70x |
Company: PE -4.12 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.292 (-109.58%) $-3.34 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 2.87 - 3.25 ( +/- 6.18%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-18 | Levin Jeremy M | Buy | 18 248 | Common Stock |
2024-02-22 | Tardio Jason | Buy | 168 750 | Stock Option (Right to Buy) |
2024-02-22 | Tardio Jason | Buy | 28 125 | Common Stock |
2024-02-22 | Rona Jeffrey A | Buy | 28 125 | Common Stock |
2024-02-22 | Rona Jeffrey A | Buy | 168 750 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
21.71 |
Last 96 transactions |
Buy: 16 581 029 | Sell: 7 414 277 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.05 (0.00% ) |
Volume | 0.138 mill |
Avg. Vol. | 0.211 mill |
% of Avg. Vol | 65.19 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.